AR077876A1 - Ligandos del receptor sigma para la prevencion o el tratamiento de dolor inducido por quimioterapia - Google Patents

Ligandos del receptor sigma para la prevencion o el tratamiento de dolor inducido por quimioterapia

Info

Publication number
AR077876A1
AR077876A1 ARP100102983A ARP100102983A AR077876A1 AR 077876 A1 AR077876 A1 AR 077876A1 AR P100102983 A ARP100102983 A AR P100102983A AR P100102983 A ARP100102983 A AR P100102983A AR 077876 A1 AR077876 A1 AR 077876A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
nr8r9
heterocyclyl
aromatic
Prior art date
Application number
ARP100102983A
Other languages
English (en)
Spanish (es)
Inventor
Jose Manuel Baeyens-Cabrera
Helmut Heinrich Buschmann
Hernandez Jose Miguel Vela
Daniel Zamanillo-Castanedo
Francisco-Rafael Nieto-Lopez
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of AR077876A1 publication Critical patent/AR077876A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP100102983A 2009-08-14 2010-08-13 Ligandos del receptor sigma para la prevencion o el tratamiento de dolor inducido por quimioterapia AR077876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382144A EP2292236A1 (en) 2009-08-14 2009-08-14 Sigma ligands for the prevention or treatment of pain induced by chemotherapy

Publications (1)

Publication Number Publication Date
AR077876A1 true AR077876A1 (es) 2011-09-28

Family

ID=41531868

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102983A AR077876A1 (es) 2009-08-14 2010-08-13 Ligandos del receptor sigma para la prevencion o el tratamiento de dolor inducido por quimioterapia

Country Status (34)

Country Link
US (3) US20120141606A1 (enExample)
EP (2) EP2292236A1 (enExample)
JP (1) JP5922575B2 (enExample)
KR (3) KR20170125951A (enExample)
CN (1) CN102497864B (enExample)
AR (1) AR077876A1 (enExample)
AU (2) AU2010283761B2 (enExample)
BR (1) BR112012003053A2 (enExample)
CA (1) CA2770441C (enExample)
CO (1) CO6511240A2 (enExample)
CY (1) CY1116697T1 (enExample)
DK (1) DK2464356T3 (enExample)
EC (1) ECSP12011658A (enExample)
ES (1) ES2543645T3 (enExample)
HR (1) HRP20150788T1 (enExample)
HU (1) HUE025642T2 (enExample)
IL (1) IL217911A0 (enExample)
IN (1) IN2012DN02149A (enExample)
MA (1) MA33569B1 (enExample)
MX (1) MX2012001877A (enExample)
MY (1) MY157334A (enExample)
NZ (1) NZ598213A (enExample)
PH (1) PH12012500286A1 (enExample)
PL (1) PL2464356T3 (enExample)
PT (1) PT2464356E (enExample)
RU (1) RU2543382C2 (enExample)
SG (1) SG178338A1 (enExample)
SI (1) SI2464356T1 (enExample)
SM (1) SMT201500189T1 (enExample)
TN (1) TN2012000048A1 (enExample)
TW (1) TWI529168B (enExample)
UA (1) UA108859C2 (enExample)
WO (1) WO2011018487A1 (enExample)
ZA (1) ZA201200843B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
MX2016002892A (es) * 2013-09-12 2016-06-10 Esteve Labor Dr Combinaciones de ligando de receptores sigma y aine.
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
MX2016007286A (es) 2013-12-17 2016-08-04 Esteve Labor Dr Combinaciones de gabapentinoides y ligandos de receptores sigma.
AR108682A1 (es) * 2016-06-06 2018-09-12 Esteve Labor Dr Derivados de pirazol-3-iloxi ligandos del receptor sigma
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2024105225A1 (en) * 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
FR2301250A1 (fr) * 1975-02-21 1976-09-17 Bellon Labor Sa Roger Nouveaux diaryl-1, 4o-aminoalcoxy-3 pyrazoles et leurs sels
MX2007002341A (es) * 2004-08-27 2007-09-25 Esteve Labor Dr Inhibidores del receptor sigma.
KR101352012B1 (ko) * 2004-08-27 2014-01-15 라보라토리오스 델 드라. 에스테브.에스.에이. 시그마 수용체 저해제
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
CN101395157A (zh) * 2006-03-01 2009-03-25 伊斯特芬博士实验室有限公司 作为西格玛受体抑制剂的吡唑衍生物
WO2007098953A1 (en) * 2006-03-01 2007-09-07 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors

Also Published As

Publication number Publication date
MY157334A (en) 2016-05-31
KR20170125951A (ko) 2017-11-15
UA108859C2 (uk) 2015-06-25
AU2016228207A1 (en) 2016-11-03
AU2010283761B2 (en) 2016-10-13
US20160199380A1 (en) 2016-07-14
US20160220575A1 (en) 2016-08-04
ES2543645T3 (es) 2015-08-20
WO2011018487A1 (en) 2011-02-17
RU2543382C2 (ru) 2015-02-27
CA2770441A1 (en) 2011-02-17
TWI529168B (zh) 2016-04-11
IL217911A0 (en) 2012-03-29
EP2464356B1 (en) 2015-05-06
DK2464356T3 (en) 2015-07-13
NZ598213A (en) 2014-05-30
CY1116697T1 (el) 2017-03-15
CN102497864B (zh) 2015-07-22
AU2010283761A1 (en) 2012-03-08
US20120141606A1 (en) 2012-06-07
HK1171945A1 (en) 2013-04-12
TN2012000048A1 (en) 2013-09-19
MA33569B1 (fr) 2012-09-01
EP2292236A1 (en) 2011-03-09
JP2013501754A (ja) 2013-01-17
MX2012001877A (es) 2012-04-11
JP5922575B2 (ja) 2016-05-24
SG178338A1 (en) 2012-03-29
ZA201200843B (en) 2012-10-31
AU2016228207B2 (en) 2017-09-07
CN102497864A (zh) 2012-06-13
CA2770441C (en) 2017-12-12
SMT201500189T1 (it) 2015-09-07
KR101605151B1 (ko) 2016-03-21
BR112012003053A2 (pt) 2016-08-02
ECSP12011658A (es) 2012-03-30
EP2464356A1 (en) 2012-06-20
SI2464356T1 (sl) 2015-08-31
RU2012109554A (ru) 2013-09-20
PT2464356E (pt) 2015-08-31
KR20120055692A (ko) 2012-05-31
KR20150140419A (ko) 2015-12-15
PL2464356T3 (pl) 2015-10-30
CO6511240A2 (es) 2012-08-31
TW201121959A (en) 2011-07-01
HRP20150788T1 (hr) 2015-08-28
HUE025642T2 (en) 2016-04-28
IN2012DN02149A (enExample) 2015-08-07
PH12012500286A1 (en) 2015-06-26

Similar Documents

Publication Publication Date Title
AR086632A1 (es) Ligandos sigma para la prevencion y/o el tratamiento de la emesis inducida por quimioterapia o radioterapia
AR084730A1 (es) Ligandos heterociclicos nitrogenados de receptores sigma utiles para el tratamiento de dolor por cancer de huesos
AR082441A1 (es) Uso de ligandos sigma en la hiperalgesia inducida por opioides
AR086636A1 (es) Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen
CO6410301A2 (es) 1 aril -3- aminoalcoxi-pirazoles como ligandos sigma para potenciar ell efecto analgesico de los opioides y atenuar la dependencia de ellos
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR081623A1 (es) Ligandos sigma para la potenciacion del efecto analgesico de opioides y opiatos en el dolor posoperatorio y la atenuacion de la dependencia a los mismos
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR100691A1 (es) Esteroides neuroactivos, composiciones, y usos de los mismos
AR101189A1 (es) Heterociclos nitrogenados antiproliferativos y sus métodos de uso
AR066583A1 (es) Derivados de 3,3-espiroindolinona
AR096709A1 (es) Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv)
AR120174A1 (es) Inhibidores del factor d del complemento para administración oral
AR070459A1 (es) Derivados de 2-aza-biciclo- [2,2,1] heptano
AR080134A1 (es) Ligandos sigma para la prevencion y/o el tratamiento del dolor postoperatorio
AR057716A1 (es) Inhibidores de las serina proteasas y composiciones farmaceuticas
FR3037957B1 (fr) Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR070502A1 (es) Derivado de sulfonilmalonamida, su uso farmaceutico y composiciones que los comprenden
AR101637A1 (es) Combinaciones de gabapentinoides y ligandos de receptores sigma
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
AR061015A1 (es) Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto
HRP20150788T1 (hr) Sigma ligandi za sprjeäśavanje ili lijeäśenje boli izazvane kemoterapijom
AR068423A1 (es) Compuesto, composicion farmaceutica y uso del compuesto en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina-3 (h3) y proceso para la preparacion del compuesto

Legal Events

Date Code Title Description
FB Suspension of granting procedure